In the US market, Aniline prices witnessed an increase of x.xx in August xxxx amid a shift in market demand and insufficient availability of supplies. In the pharma sector, the demand and offtakes of Aniline were consistent. Moderna experienced an xx.xx increase in market capitalization, largely due to the US FDA&#xx;s approval of its mRNA respiratory syncytial virus (RSV) vaccine, mRESVIA, in May xxxx. This approval represents a significant milestone for Moderna, as it is the company&#xx;s second mRNA product to receive regulatory approval. The boost in market capitalization underscores investor confidence and the growing impact of Moderna&#xx;s innovative vaccine portfolio in the biotechnology sector. Additionally, in July xxxx, the Consumer Price Index (CPI) increased by x.xx from the previous month and x.xx compared to last year.
At the same time, the Aniline production rates were moderate at Asian manufacturing units, and the...
